Q2 2026 saw 5% sales growth to £8.4bn, with core operating profit up 7% and EPS up 9%. Specialty Medicines and Vaccines drove performance, while the Accelerate Growth programme is reallocating capital to late-stage R&D. Guidance for 2026 remains at the upper end for sales and profit.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.